Expression Of Major Intracellular Components of the NF-κB Alternative Pathway (NF-κB2, RelB, NIK and Bcl3) is Associated With Clinical Outcome of NSCLC Patients

^{1§}Foteinos-Ioannis D. Dimitrakopoulos, ^{1§}Anna G. Antonacopoulou, ^{1§}Anastasia E. Kottorou, ²Nikolaos Panagopoulos, ¹Fotini Kalofonou, ³Fotios Sampsonas, ⁴Chrisoula Scopa, ⁵Melpomeni Kalofonou, ¹Angelos Koutras, ¹Thomas Makatsoris, ²Dimitrios Dougenis, ⁶Helen Papadaki, ⁷Malcolm Brock, ^{1*}Haralabos P. Kalofonos

¹Molecular Oncology Laboratory, Division of Oncology, Department of Internal Medicine, Medical School, University of Patras, Patras, Greece.

⁷Division of Thoracic Surgery, Department of Surgery, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.

§ These authors contributed equally to this work.

*Corresponding author: Prof. Haralabos P. Kalofonos, Division of Oncology, Department of Internal Medicine, Medical School, University of Patras, Rion-Patras 26504, Greece. Tel.: +30 261099535, Fax: +30 2610994645, E-mail: kalofonos@upatras.gr


² Department of Cardiothoracic Surgery, Medical School, University of Patras, Patras, Greece.

³ Department of Respiratory Medicine, University Hospital of Patras, Patras, Greece.

⁴Department of Pathology, Medical School, University of Patras, Patras, Greece.

⁵Institute of Biomedical Engineering, Imperial College London, London, United Kingdom.

⁶Department of Anatomy, Medical School, University of Patras, Patras, Greece.



Supplementary Figure 3. Boxplot of a) cytoplasmic RelB expression, b) nuclear RelB expression and c) NIK cytoplasmic expression in relation to histological subtype.